FARMINGTON, Conn., Sept. 13, 2012 /PRNewswire-iReach/ -- Global Information Inc. is pleased to announce a limited time offer on personalized medicine, next generation sequencing (NGS) and epigenetics research from Takeda Pacific, a bio/pharmaceutical and life sciences industry analyst firm based in California.
Personalized Medicine: Companies, Trends and World Market
The Personalized Medicine market includes significant core medical product areas that will continue to have a powerful impact on current and future healthcare delivery. The science driving personalized medicine includes pharmacogenetics, pharmacogenproteomics and pharmacometabalomix. Personalized medicine uses a targeted drug that depends on the patient information identified by a companion diagnostic (genetic biomarker test).
This report examines key market segments such as targeted drugs and key personalized medicine diagnostics, including companion diagnostic IVDs, LDTs, diagnostic services and related tools or technologies. Important technologies examined include: microarray, next-generation sequencing, polymerase chain reaction (PCR), bioinformatics, nanotechnology and other platforms. The report highlights new personalized diagnostics and also covers key biomarkers, commercial diagnostics and therapeutics that drive personalized medicine.
Save up to 20% by purchasing this report before October 15, 2012.
For a detailed executive summary, sample charts, and table of contents, or to request free sample pages from the full report, please visit http://www.giiresearch.
|SOURCE Global Information, Inc.|
Copyright©2012 PR Newswire.
All rights reserved